Advanced

Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival.

Gustafsson, Anna LU ; Martuszewska, Danuta LU ; Johansson, Martin LU ; Ekman, Carl LU ; Hafizi, Sassan LU ; Ljungberg, Börje and Dahlbäck, Björn LU (2009) In Clinical Cancer Research 15(14). p.4742-4749
Abstract
PURPOSE: Overexpression of the receptor tyrosine kinase Axl is implicated in several cancers. Therefore, we conducted this study to determine the expression of Axl and its ligand Gas6 in various renal cell carcinoma (RCC) types and in oncocytoma. EXPERIMENTAL DESIGN: Real-time quantitative reverse transcription-PCR was used to quantify tumor mRNA levels for Axl and Gas6 in a cohort (n = 221) of RCC patients. Serum levels of soluble sAxl and Gas6 proteins were measured using specific ELISA assays (n = 282). The presence of Axl protein in tumor tissue was evaluated by immunohistochemistry (n = 294). Results were correlated to tumor-associated variables, clinical biochemical tests, and patient survival. RESULTS: Tumor Axl mRNA levels... (More)
PURPOSE: Overexpression of the receptor tyrosine kinase Axl is implicated in several cancers. Therefore, we conducted this study to determine the expression of Axl and its ligand Gas6 in various renal cell carcinoma (RCC) types and in oncocytoma. EXPERIMENTAL DESIGN: Real-time quantitative reverse transcription-PCR was used to quantify tumor mRNA levels for Axl and Gas6 in a cohort (n = 221) of RCC patients. Serum levels of soluble sAxl and Gas6 proteins were measured using specific ELISA assays (n = 282). The presence of Axl protein in tumor tissue was evaluated by immunohistochemistry (n = 294). Results were correlated to tumor-associated variables, clinical biochemical tests, and patient survival. RESULTS: Tumor Axl mRNA levels correlated independently to survival when assessed against tumor stage and grade. In the study group, the median cancer-specific survival of all RCC patients during 307 months of follow-up was 55 months (confidence interval, +/-40.4). The 25% of patients with lowest tumor Axl mRNA levels had significantly better survival than the rest (P = 0.0005), with 70% of the patients still alive at the end of follow-up. In contrast, in patients with medium-high Axl mRNA, only 25% were alive at the end of follow-up. Tumor Gas6 mRNA levels correlated to survival, tumor-associated variables, and disease severity as did serum levels of soluble sAxl and Gas6 protein. However, no correlation between Axl protein in tumor tissue and survival was found. CONCLUSIONS: Axl and Gas6 expression in RCC are associated with tumor advancement and patient survival. In particular, low tumor Axl mRNA levels independently correlated with improved survival. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Clinical Cancer Research
volume
15
issue
14
pages
4742 - 4749
publisher
American Association for Cancer Research
external identifiers
  • wos:000268908400029
  • pmid:19567592
  • scopus:68049096311
ISSN
1078-0432
DOI
10.1158/1078-0432.CCR-08-2514
language
English
LU publication?
yes
id
378f93b2-4b40-44b9-ac9b-e59dbbedd583 (old id 1453465)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19567592?dopt=Abstract
date added to LUP
2009-08-04 09:12:49
date last changed
2017-12-10 04:41:40
@article{378f93b2-4b40-44b9-ac9b-e59dbbedd583,
  abstract     = {PURPOSE: Overexpression of the receptor tyrosine kinase Axl is implicated in several cancers. Therefore, we conducted this study to determine the expression of Axl and its ligand Gas6 in various renal cell carcinoma (RCC) types and in oncocytoma. EXPERIMENTAL DESIGN: Real-time quantitative reverse transcription-PCR was used to quantify tumor mRNA levels for Axl and Gas6 in a cohort (n = 221) of RCC patients. Serum levels of soluble sAxl and Gas6 proteins were measured using specific ELISA assays (n = 282). The presence of Axl protein in tumor tissue was evaluated by immunohistochemistry (n = 294). Results were correlated to tumor-associated variables, clinical biochemical tests, and patient survival. RESULTS: Tumor Axl mRNA levels correlated independently to survival when assessed against tumor stage and grade. In the study group, the median cancer-specific survival of all RCC patients during 307 months of follow-up was 55 months (confidence interval, +/-40.4). The 25% of patients with lowest tumor Axl mRNA levels had significantly better survival than the rest (P = 0.0005), with 70% of the patients still alive at the end of follow-up. In contrast, in patients with medium-high Axl mRNA, only 25% were alive at the end of follow-up. Tumor Gas6 mRNA levels correlated to survival, tumor-associated variables, and disease severity as did serum levels of soluble sAxl and Gas6 protein. However, no correlation between Axl protein in tumor tissue and survival was found. CONCLUSIONS: Axl and Gas6 expression in RCC are associated with tumor advancement and patient survival. In particular, low tumor Axl mRNA levels independently correlated with improved survival.},
  author       = {Gustafsson, Anna and Martuszewska, Danuta and Johansson, Martin and Ekman, Carl and Hafizi, Sassan and Ljungberg, Börje and Dahlbäck, Björn},
  issn         = {1078-0432},
  language     = {eng},
  number       = {14},
  pages        = {4742--4749},
  publisher    = {American Association for Cancer Research},
  series       = {Clinical Cancer Research},
  title        = {Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival.},
  url          = {http://dx.doi.org/10.1158/1078-0432.CCR-08-2514},
  volume       = {15},
  year         = {2009},
}